Purchase this article with an account.
M. Al Oum, S. Donati, F. Contini, V. Viganò, M. Bianchi, P. Chelazzi, P. Sivelli, C. Azzolini; Fundus Autofluorescence Evaluation in Exudative Macular Degeneration After Intravitreal Bevacizumab Treatment. Invest. Ophthalmol. Vis. Sci. 2009;50(13):5255.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
to evaluate the predictive value of fundus autofluorescence after intravitreal bevacizumab treatment in exudative age related macular degeneration.
On evaluated patients, baseline mean VA was 0.3 and mean central macular thickness (CMT) was 550µm; at day 90, 0.34 and 460 µm; at day 180, mean VA was 0.35 and CMT 483 µm. At baseline macular AF appeared increased in all 23 patients. At day 90, AF was increased in 7 patients (30.5%), decreased in 5 (21.7%), stable in 11 (47.8%) patients. At day 180, AF was increased in 3 (13%) patients, decreased in 1 (4%), stable in 19 (83%) patients. Our data analysis showed at day 180 a visual improvement in 4 patients (20%) with stable FAF and on the patient with decreased macular FAF; visual acuity decreased significantly in all 3 patients with increased FAF at day 180. Visual acuity remained stable in 6 patients (33%) with unchanged FAF.
Our study showed the prognostic factor of FAF in patients treated with antiVEGF for exudative AMD. A decrease or stability of FAF during follow up was related to a VA preservation or improvement; increasing FAF with VA worsening. The evaluation of retinal-pigment epithelium degeneration, according to angiography and OCT examination represents a new functional parameter for anti VEGF treatment. Further studies will be performed with microperimetry evaluation, to better investigate functional parameters aside visual acuity as retinal fixation and macular sensibility.
This PDF is available to Subscribers Only